U.S. flag An official website of the United States government
  1. Home
  2. For Industry
  3. Developing Products for Rare Diseases & Conditions
  4. Designating an Orphan Product: Drugs and Biological Products
  5. Orphan Drug Regulations: Regulatory History
  1. Developing Products for Rare Diseases & Conditions

Orphan Drug Regulations: Regulatory History

Orphan Drug Regulations: Regulatory History

On June 12, 2013, the Food and Drug Administration (FDA) issued a final rule (78 FR 35117) amending the 1992 Orphan Drug Regulations, which implement the Orphan Drug Act (ODA, Relevant Excerpts: Public Law 97-414, as amended). This final rule is effective as of August 12, 2013 and is codified at 21 CFR part 316 .

These amendments are intended to clarify certain regulatory language and propose areas of minor improvement regarding orphan-drug designation and orphan-drug exclusivity. FDA believes these revisions clarify, streamline, and improve the orphan-drug designation process.

These amendments are fully consistent with the Orphan Drug Act (ODA, Relevant Excerpts: Public Law 97-414) and continue to provide incentives for the development of potentially promising orphan drugs that may not otherwise be developed and approved, including drugs that are potentially safer or more effective than already approved drugs.

 

 

 Orphan Drug Final Rule of June 12, 2013 

 Orphan Drug Proposed Rule of October 19, 2011

 Orphan Drug Final Rule of December 29, 1992

 Orphan Drug Proposed Rule of January 29, 1991

If you have questions about the 2013 Final Rule and this regulatory history, please contact:

Ms. Erica K. McNeilly

Tel: 301-796-8679

Email: erica.mcneilly@fda.hhs.gov